Continuing Education Lunch Symposium
Wednesday, June 24, 2015
12:00 – 12:15 PM Lunch
12:15 – 13:45 PM Symposium
Metro Toronto Convention Centre
Room 701, Level 700
222 Bremner Boulevard
Toronto, Ontario, Canada
Statement of Need/Program Overview
Anticoagulant drug use will continue to rise in the near future, particularly given the rapidly expanding population over the age of 65 years. In the past decade, new oral anticoagulants (NOACs) have been approved for the prophylaxis and treatment of thromboembolism. These newer agents are advantageous with a short half-life, fewer food and drug interactions, and lack of requirement for monitoring of the international normalized ratio. In contrast to the vitamin K antagonists such as warfarin, which have vitamin K as a proven antidote, there are currently no specific agents for reversal of NOACs. Use of NOACs can present a challenge given the risk of bleeding and the occasional need for urgent reversal when patients present with bleeding complications or prior to urgent interventional procedures. Various therapeutic approaches include the use of vitamin K, plasma, prothrombin complex concentrates (PCCs), activated PCCs, recombinant factor VIIa, and emerging NOAC reversal agents. In this activity, expert faculty will evaluate therapeutic strategies to reverse the anticoagulant state, review current evidence for reversal of anticoagulants, and suggest practical clinical strategies for management of patients receiving older and newer anticoagulants.
If you have any questions please contact Mark Davis at 866-512-8802.
This activity is jointly provided by Postgraduate Institute for Medicine and CMEology.
This activity is supported by an educational grant from Baxalta US Inc.